Zobrazeno 1 - 10
of 214
pro vyhledávání: '"Ming-Qing Xu"'
Autor:
Chang Liu, Lei Li, Wu-sheng Lu, Hua Du, Lu-nan Yan, Tian-fu Wen, Wu-ran Wei, Li Jiang, Ming-qing Xu
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-9 (2018)
Abstract Background There is currently limited information regarding the prognostic ability of the dNLR-PNI (the combination of the derived neutrophil-to-lymphocyte ratio [dNLR] and prognostic nutritional index [PNI]) for hepatocellular carcinoma (HC
Externí odkaz:
https://doaj.org/article/a26a524f6428473fad36500135bffaaa
Autor:
Chuan Li, M.D., Tian-Fu Wen, Lu-Nan Yan, Bo Li, Jia-Ying Yang, Ming-Qing Xu, Wen-Tao Wang, Yong-Gang Wei
Publikováno v:
Annals of Hepatology, Vol 11, Iss 4, Pp 471-477 (2012)
Background. Living donor liver transplantation (LDLT) for patients with high model for end-stage liver disease (MELD) scores is controversial due to its poor outcome. However, there is little information regarding which factor would negatively impact
Externí odkaz:
https://doaj.org/article/adade281221f4e5298bbf766df84360d
Autor:
Chuan Li, Tian-Fu Wen, Lu-Nan Yan, Bo Li, Jia-Ying Yang, Ming-Qing Xu, Wen-Tao Wang, Yong-Gang Wei
Publikováno v:
PLoS ONE, Vol 8, Iss 8, p e72235 (2013)
AIM: The selection criteria for patients with hepatocellular carcinoma (HCC) to undergo liver transplantation should accurately predict posttransplant recurrence while not denying potential beneficiaries. In the present study, we attempted to identif
Externí odkaz:
https://doaj.org/article/b1495fc3400e4bcda563c863d42b2586
Publikováno v:
Aging (Albany NY)
Antitumor immunotherapy can enable promising and durable responses following their clinical application. However, heterogeneity in the tumor immune microenvironment leads to differences in the individual response rates. In this study, we identified n
Autor:
Li Feng, Jiao Zhu, Xiujing He, Yunfan Yin, Ming Zhang, Ming-Qing Xu, Xiaobo Zheng, Jing Yu, Chune Yu
Publikováno v:
Aging (Albany NY)
As a key mechanism, alternative splicing (AS) plays a role in the cancer initiation and development. However, in papillary thyroid cancer (PTC), data for the comprehensive AS event profile and its clinical implications are lacking. Herein, a genome-w
Publikováno v:
J Gastrointest Oncol
BACKGROUND: Many complications after hepatectomy can lead to perioperative death, among which posthepatectomy liver failure (PHLF) is the leading one. Existing studies suggest that one of the most important risk factors for PHLF is cirrhosis. Hepatit
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-14 (2021)
Scientific Reports
Scientific Reports
Immunotherapy involving immune checkpoint inhibitors (ICIs) for enhancing immune system activation is promising for tumor management. However, the patients’ responses to ICIs are different. Here, we applied a non-negative matrix factorization algor
Publikováno v:
Clinica Chimica Acta. 511:107-116
Background Our study aimed to formulate a nomogram based on the albumin-to-fibrinogen ratio (AFR) and gamma-glutamyl transpeptidase-to-platelet ratio (GPR) to predict the prognosis of hepatocellular carcinoma (HCC) patients after curative hepatic res
Autor:
Lvnan Yan, Liangliang Xu, Tian-Fu Wen, Yanfang Zhang, Xiangyong Hao, Ming-Qing Xu, Ming Zhang, Lian Li, Peng Wang, Bo Li
Publikováno v:
Gut and Liver
Background/Aims Microvascular invasion (MVI) is an established risk factor for hepatocellular carcinoma (HCC). However, prediction models that specifically focus on the individual prognoses of HCC patients with MVI is lacking. Methods A total of 385
Publikováno v:
Ann Transl Med
Background Sorafenib, hepatectomy, and transarterial chemoembolization (TACE) are the recommended treatment for portal vein tumor thrombosis (PVTT) patients. Therefore, the aim of the present study was to conduct a multi-treatment meta-analysis. The